Personalized medicine has been a popular topic in the last few years, but when will it materialize? Experts discussed the current challenges at Labiotech Refresh.

Jean-Pol Detiffe is the CEO of OncoDNA, a company using next-generation sequencing to match patients with a personalized cancer treatment. In his opinion, one of the main challenges in the field is that “biology is complex and a successful test cannot only rely on genes“. His company addresses it by also looking at RNA and methylation. He also highlighted liquid biopsy as a big trend in the field: “we have developed a personalized blood test to see if cancer is coming back, focusing on following up with the patients“.

Marjolaine Barldo is Head EMEA at Agendia, a company with a diagnostic test that can reduce the use of chemotherapy by 46% in patients with breast cancer. Mammaprint is one of the first diagnostic tests to show robust clinical results that could lead to reimbursement, a big challenge in the area of personalized medicine. “The EU is starting to open for reimbursement“, she reckons. Her test is currently on conditional reimbursement for 3 years, during which the company is evaluating the real outcome of the genomic assay with amazing results so far.

Jemila Houacine, Associate at Medicxi, provided an investor’s perspective: “integrating specific biomarkers and drugs and adjusting trial design to accelerate development is the next big thing“. She believes that the increasing implication of patients will be a game changer.

To get all the details on the next big trends in the promising area of personalized medicine, watch the video of our expert panel at Labiotech Refresh.

Previous post

This SynBio Start-up is Redefining the Rules of Evolution

Next post

From Berlin with Fireworks: We wish you a Happy New Year 2017!